{
  "request": {
    "url": "https://query2.finance.yahoo.com/ws/insights/v2/finance/insights?lang=en-US&region=US&getAllResearchReports=true&reportsCount=2&symbol=ABBV"
  },
  "response": {
    "ok": true,
    "status": 200,
    "statusText": "OK",
    "headers": {
      "content-type": [
        "application/json;charset=utf-8"
      ],
      "cache-control": [
        "public, max-age=300, stale-while-revalidate=120"
      ],
      "vary": [
        "Origin,Accept-Encoding"
      ],
      "y-rid": [
        "eh91bi9h29j2j"
      ],
      "x-yahoo-request-id": [
        "eh91bi9h29j2j"
      ],
      "x-request-id": [
        "7e37d7e0-2a0b-4170-b74b-ff101b5cedde"
      ],
      "content-encoding": [
        "gzip"
      ],
      "content-length": [
        "2397"
      ],
      "x-envoy-upstream-service-time": [
        "5"
      ],
      "date": [
        "Sun, 06 Mar 2022 14:59:30 GMT"
      ],
      "server": [
        "ATS"
      ],
      "x-envoy-decorator-operation": [
        "finance-market-analytics-api--mtls-production-ir2.finance-k8s.svc.yahoo.local:4080/*"
      ],
      "age": [
        "1"
      ],
      "strict-transport-security": [
        "max-age=15552000"
      ],
      "referrer-policy": [
        "no-referrer-when-downgrade"
      ],
      "x-frame-options": [
        "SAMEORIGIN"
      ],
      "connection": [
        "close"
      ],
      "expect-ct": [
        "max-age=31536000, report-uri=\"http://csp.yahoo.com/beacon/csp?src=yahoocom-expect-ct-report-only\""
      ],
      "x-xss-protection": [
        "1; mode=block"
      ],
      "x-content-type-options": [
        "nosniff"
      ]
    },
    "bodyJson": {
      "finance": {
        "result": {
          "symbol": "ABBV",
          "instrumentInfo": {
            "technicalEvents": {
              "provider": "Trading Central",
              "sector": "Healthcare",
              "shortTermOutlook": {
                "stateDescription": "Bullish events outweigh bearish events.",
                "direction": "Bullish",
                "score": 2,
                "scoreDescription": "Bullish Evidence",
                "sectorDirection": "Bullish",
                "sectorScore": 3,
                "sectorScoreDescription": "Strong Bullish Evidence",
                "indexDirection": "Bearish",
                "indexScore": 1,
                "indexScoreDescription": "Weak Bearish Evidence"
              },
              "intermediateTermOutlook": {
                "stateDescription": "All events are bullish.",
                "direction": "Bullish",
                "score": 1,
                "scoreDescription": "Weak Bullish Evidence",
                "sectorDirection": "Bearish",
                "sectorScore": 1,
                "sectorScoreDescription": "Weak Bearish Evidence",
                "indexDirection": "Bearish",
                "indexScore": 3,
                "indexScoreDescription": "Strong Bearish Evidence"
              },
              "longTermOutlook": {
                "stateDescription": "All events are bullish.",
                "direction": "Bullish",
                "score": 2,
                "scoreDescription": "Bullish Evidence",
                "sectorDirection": "Bullish",
                "sectorScore": 2,
                "sectorScoreDescription": "Bullish Evidence",
                "indexDirection": "Bearish",
                "indexScore": 2,
                "indexScoreDescription": "Bearish Evidence"
              }
            },
            "keyTechnicals": {
              "provider": "Trading Central",
              "support": 116.2799,
              "resistance": 150.79,
              "stopLoss": 142.961141
            },
            "valuation": {
              "color": 0,
              "description": "Overvalued",
              "discount": "-21%",
              "relativeValue": "Premium",
              "provider": "Trading Central"
            }
          },
          "companySnapshot": {
            "sectorInfo": "Healthcare",
            "company": {
              "innovativeness": 0.9571,
              "hiring": 0.919,
              "sustainability": 0.7759999999999999,
              "insiderSentiments": 0.1307,
              "earningsReports": 0.9117000000000001,
              "dividends": 0.8633
            },
            "sector": {
              "innovativeness": 0.5,
              "hiring": 0.5,
              "sustainability": 0.5,
              "insiderSentiments": 0.5,
              "earningsReports": 0.5,
              "dividends": 0.5
            }
          },
          "recommendation": {
            "targetPrice": 165,
            "provider": "Argus Research",
            "rating": "BUY"
          },
          "upsell": {
            "msBullishSummary": [
              "AbbVie supports a strong dividend yield, which should act as valuation support, as the cash flows to support the dividend look secure over the next few years. ",
              "AbbVie's increasing entrenchment in blood cancers should bode well for growth as pricing power remains solid in this therapeutic area of the pharmaceutical market.",
              "AbbVie's next generation immunology drugs targeting the IL23 and JAK pathways should help mitigate the competitive threats facing Humira."
            ],
            "msBearishSummary": [
              "Several of AbbVie's pipeline drugs in immunology have mechanisms of action similar to drugs already approved, taking away the first mover advantage for AbbVie.",
              "The high profit margins on Humira will likely cause an amplified impact on earnings as sales are lost to eventual biosimilar competition.",
              "The extra debt needed to finance the Allergan deal could put amplified pressure on AbbVie if core assets like Botox and Humira face tougher competition than expected."
            ],
            "companyName": "AbbVie Inc.",
            "msBullishBearishSummariesPublishDate": 1643825717000,
            "upsellReportType": "MORNINGSTAR_ANALYST"
          },
          "upsellSearchDD": {
            "researchReports": {
              "reportId": "ARGUS_3610_AnalystReport_1644498460000",
              "provider": "Argus",
              "title": "Reaffirming BUY; raising target to $165",
              "reportDate": "2022-02-10T13:07:40Z",
              "summary": "AbbVie, a research-based biopharmaceutical company, was spun off from Abbott Laboratories in January 2013. The company is based in suburban Chicago. The shares are a component of the S&P 500.",
              "investmentRating": "Bullish"
            }
          },
          "events": [
            {
              "eventType": "Relative Strength Index (RSI)",
              "pricePeriod": "D",
              "tradingHorizon": "S",
              "tradeType": "S",
              "imageUrl": "https://s.yimg.com/uc/fin/img/assets/generic.svg",
              "startDate": 1646058600,
              "endDate": 1646058600
            }
          ],
          "reports": [
            {
              "id": "ARGUS_32286_TopBottomInsiderActivity_1646289377000",
              "headHtml": "Daily – Vickers Top Buyers & Sellers for 03/03/2022",
              "provider": "Argus Research",
              "reportDate": "2022-03-03T06:36:17Z",
              "reportTitle": "The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.",
              "reportType": "Top/Bottom Insider Activity"
            },
            {
              "id": "ARGUS_32275_TopBottomInsiderActivity_1646202512000",
              "headHtml": "Daily – Vickers Top Buyers & Sellers for 03/02/2022",
              "provider": "Argus Research",
              "reportDate": "2022-03-02T06:28:32Z",
              "reportTitle": "The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.",
              "reportType": "Top/Bottom Insider Activity"
            }
          ],
          "sigDevs": [
            {
              "headline": "Abbvie Provides Update Regarding Skyrizi (Risankizumab-Rzaa) For The Treatment Of Moderate To Severe Crohn's Disease In The U.S.",
              "date": "2022-02-28"
            }
          ],
          "secReports": [
            {
              "id": "0001104659-22-030613_1551152",
              "type": "Corporate Changes & Voting Matters",
              "title": "8-K : Corporate Changes & Voting Matters",
              "description": "Current report filing",
              "filingDate": 1646352000000,
              "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0001551152/000110465922030613/thumbnail.png",
              "formType": "8-K"
            },
            {
              "id": "0001104659-22-025712_1551152",
              "type": "Offering Registrations",
              "title": "S-3ASR : Offering Registrations",
              "description": "Automatic shelf registration statement of securities of well-known seasoned issuers",
              "filingDate": 1645488000000,
              "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0001551152/000110465922025712/thumbnail.png",
              "formType": "S-3ASR"
            },
            {
              "id": "0001551152-22-000007_1551152",
              "type": "Periodic Financial Reports",
              "title": "10-K : Periodic Financial Reports",
              "description": "Annual report pursuant to Section 13 and 15(d)",
              "filingDate": 1645142400000,
              "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/1551152/000155115222000007/thumbnail.png",
              "formType": "10-K"
            },
            {
              "id": "0001104659-22-016352_1551152",
              "type": "Tender Offer/Acquisition Reports",
              "title": "SC 13G/A : Tender Offer/Acquisition Reports",
              "description": "Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions",
              "filingDate": 1644364800000,
              "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0001551152/000110465922016352/thumbnail.png",
              "formType": "SC 13G/A"
            },
            {
              "id": "0000834237-22-006222_1551152",
              "type": "Tender Offer/Acquisition Reports",
              "title": "SC 13G/A : Tender Offer/Acquisition Reports",
              "description": "Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions",
              "filingDate": 1643846400000,
              "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/0001551152/000083423722006222/thumbnail.png",
              "formType": "SC 13G/A"
            },
            {
              "id": "0001551152-22-000003_1551152",
              "type": "Corporate Changes & Voting Matters",
              "title": "8-K : Corporate Changes & Voting Matters",
              "description": "Current report filing",
              "filingDate": 1643760000000,
              "snapshotUrl": "https://cdn.yahoofinance.com/prod/sec-reports-thumbnails/1551152/000155115222000003/thumbnail.png",
              "formType": "8-K"
            }
          ]
        },
        "error": null
      }
    }
  }
}